Susan Horvath
2021
In 2021, Susan Horvath earned a total compensation of $557.1K as Chief Financial Officer and Vice President of Finance at Panbela Therapeutics, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $99,620 |
|---|---|
| Option Awards | $155,258 |
| Salary | $302,200 |
| Total | $557,078 |
Horvath received $302.2K in salary, accounting for 54% of the total pay in 2021.
Horvath also received $99.6K in non-equity incentive plan and $155.3K in option awards.
Rankings
In 2021, Susan Horvath's compensation ranked 10,479th out of 12,406 executives tracked by ExecPay. In other words, Horvath earned more than 15.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,479 out of 12,406 | 16th |
Division Manufacturing | 4,635 out of 5,494 | 16th |
Major group Chemicals And Allied Products | 2,080 out of 2,369 | 12th |
Industry group Drugs | 1,844 out of 2,090 | 12th |
Industry Pharmaceutical Preparations | 1,365 out of 1,537 | 11th |
Source: SEC filing on April 29, 2022.
Horvath's colleagues
We found two more compensation records of executives who worked with Susan Horvath at Panbela Therapeutics in 2021.